logo

Catalyst Biosciences Inc. (CBIO)



Trade CBIO now with
  Date
  Headline
7/8/2019 5:05:09 AM Catalyst Biosciences Meets Primary Endpoint In Phase 2 Trial Of Subcutaneous Marzeptacog Alfa (Activated)
2/6/2019 8:14:19 AM Catalyst Biosciences Announces Preclinical Proof-of-Concept Data Of Gene Therapy Candidate CB 2679d-GT For Hemophilia B
12/1/2018 12:34:34 PM Catalyst Biosciences Announces Updated Positive Interim Data From Phase 2/3 Study Of Marzeptacog Alfa (Activated)
11/1/2018 8:18:24 AM Catalyst Biosciences Q3 Loss Per Share $0.64 Vs Loss $1.34 Last Year
8/15/2018 8:08:47 AM Catalyst Biosciences Says Updated Positive Interim Data From Phase 2/3 Study Of SQ Prophylactic VIIa Variant MarzAA
8/2/2018 8:16:46 AM Catalyst Biosciences Q2 Loss Attributable To Stockholders $6.5 Mln Or $0.54/Shr Vs Loss $9.8 Mln Or $2.53/Shr Last Year
7/18/2018 7:00:44 AM Catalyst Biosciences Announces Positive Interim Data From Phase 2/3 Study Of Marzeptacog Alfa (Activated)
7/10/2018 8:08:37 AM Catalyst Biosciences Appoints Grant Blouse As VP Of Translational Research
5/3/2018 8:18:11 AM Catalyst Biosciences Q1 Net Loss Attributable To Common Stockholders $5.0 Mln Or $0.56/Shr
4/12/2018 8:17:54 AM Catalyst : S. Korea Oks Addition Of Sixth Cohort To Phase 1/2 Trial Of CB 2679d/ISU304 In Individuals With Hemophilia
3/1/2018 8:50:08 AM Catalyst Biosciences FY Net Loss Attributable To Common Stockholders $25.5 Mln Or $7.45 Per Share